You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Multivalent Lyme Disease Vaccine Targeting Tick-Host-Pathogen Interactions

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    DESCRIPTION provided by applicant This proposal seeks to develop a novel vaccine against Lyme disease by targeting Ixodes scapularis proteins critical for Borrelia burgdorferi transmission from the tick to mammalian host Earlier work has identified four tick proteins Salp TRE tHRF and TSLPI that facilitate different steps of spirochete transmission and immunity against these protein ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. A serologic assay to measure successful Lyme borreliosis antibiotic therapy

    SBC: L2 DIAGNOSTICS LLC            Topic: R

    DESCRIPTION provided by applicant Lyme disease LD caused by the Ixodes tick borne spirochete Borrelia burgdorferi Bb is the most common vector borne disease in the United States Despite public health preventive measures the annual confirmed case incidence has risen to over the vast majority of which occur in the Northeast Disseminated infection causes disease in the skin heart ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Clinical development of 18F PET tracer for imaging VEGF receptors

    SBC: SIBTECH, INC.            Topic: NCI

    The overall goal of this collaborative Fast-Track project is clinical development of a novel 18F PET tracer for molecular imaging of receptors for vascular endothelial growth factor (VEGFR). This receptor is the major anti-angiogenic drug target in oncology patients. Critically, VEGFR prevalence decreases when VEGF/VEGFR anti-angiogenic inhibitors work , and increases when these drugs stop worki ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. CyanoMap: Mapping inland lake quality and Amyotrophic lateral sclerosis risk fact

    SBC: APPLIED GEOSOLUTIONS LLC            Topic: NIEHS

    DESCRIPTION provided by applicant Amyotrophic lateral sclerosis ALS is a progressive fatal neurodegenerative disease with a lifetime risk of in for a young adult Armon The average life expectancy of a person with ALS is two to five years from time of diagnosis with new cases diagnosed per year Incidence rates vary in industrialized nations an annual incidence rate of ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Dampening CAR therapy-induced cytokine storm with anti-GM-CSF antibodies

    SBC: CELDARA MEDICAL, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): The long-term aim of this project is to reduce or eliminate the serious adverse events associated with cellular immunotherapy used to treat cancer. The current impressive efficacy of chimeric antigen receptor (CAR) T cell therapies is often accompanied by a well-known toxicity stemming from the large release of cytokines from activated immune cells, known as a ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Destroying the HIV-1 provirus by utilizing components of the CRISPR/Cas system

    SBC: CELDARA MEDICAL, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this project is to develop a plasmid-based therapy that will destroy the integrated HIV-1 DNA (HIV- 1 provirus) in infected cells. Current HIV-1 anti-retroviral therapy (ARV) consists of a cocktail of drugsthat blocks viral binding and replication, but does not destroy the HIV-1 provirus. In addition, ARV does not impact the large reservoir of laten ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Development of the VirtualTAVR system for diagnostics and preventative strategies

    SBC: Dura LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Since the first procedure in there has been an explosive growth in transcatheter aortic valve replacement TAVR Up to date more than TAVR had been performed worldwide Despite the increased global experience with TAVR severe adverse events associated with TAVR have been extensively documented including annulus rupture coronary occlusion para ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Diagnostic Assays for early Lyme Borreliosis using in-vivo expressed antigens

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    DESCRIPTION provided by applicant Current testing for Lyme disease is suboptimal because it requires two assay platforms including one with subjective interpretation of results and because it has lower sensitivity in the early stage of the illness Infection with Borrelia burgdorferi the causative agent of Lyme disease is transmitted by the bite of an Ixodid tick and results in uniformly lo ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Diagnostic Biomarkers to Predict Individual Propensity to Diabetic Complications

    SBC: PREVENTAGE HEALTHCARE, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): The diabetes epidemic, and the devastating complications that accompany it, have created an unprecedented worldwide medical crisis. It is primarily the complications of diabetes, including kidney failure, blindness, cardiovascular disease and neuropathy that accounts for the 245 billion spent in 2012 in the US. A significant problem for doctors who treat diabe ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Extending an Open-Source Integrated Data Management Platform to Anxiety Disorders

    SBC: PROMETHEUS RESEARCH, LLC            Topic: 101

    DESCRIPTION provided by applicant The goal of this application is to empower anxiety disorders researchers to manage share and repurpose their research data more effectively throughout the research lifecycle by delivering an open source integrated data management platform that meets their needs Mental health research has become more complex collaborative and interdisciplinary and sharing ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government